Fig. 7
Exo-miR-155-5p suppresses tumor growth in immunocompetent mice. A. DiR-labeled exosomes (100 μg) were intravenously injected into C57/BL6 mice. The photos of liver, lung, spleen and heart were taken at 2, 12, and 24 h after the injection by In Vivo Imaging System (IVIS) spectrum. B. The schematic diagram of mice study design. C. Representative images of ascites and tumor nodes dissemination in peritoneal cavity. D. Kaplan-Meier survival curves among groups. Mice were terminated when they gained more than 40% waist circumference and/or 30% body weight or showed any signs of cachexia. Log rank P (Exo-miR-con+anti-IgG vs. Exo-miR-con+anti-PDL1) = 0.0132; P (Exo-miR-con+anti-IgG vs. Exo-miR-155 + anti- IgG) = 0.0002; P (Exo-miR-con+anti-PDL1 vs. Exo-miR-155 + anti-PDL1) = 0.0213; P (Exo-miR-155 + anti-IgG vs. Exo-miR-155 + anti-PDL1) = 0.1657. E. Waist circumference was measured weekly as an indicator of ascites accumulation (tumor progression). F. Individual waist measurements of mice over time (n = 9 in ID8-miR-con group, n = 10 in ID8-miR-155 group)